FILTER
FILTERED INTERVIEW RESULTS
Anwar Daud
MANAGING DIRECTOR, ZIM LABORATORIES
"We progressed on the development of our New Innovative Products (NIP), which are complex generics developed using in-house proprietary technology platforms."
Daniel Prince
CEO, PRINCE STERILIZATION SERVICES
"We are extremely excited about the growth our hydrogen peroxide and packaging segments can bring."
Joe Panetta
PRESIDENT AND CEO, BIOCOM CALIFORNIA
"We are beginning to see California move forward as not two or three individual clusters, but rather as a powerhouse of integrated clusters, and this will continue to be our focus in the future."
Kendalle Burlin O’Connell
CEO AND PRESIDENT, MASSBIO
"In 2023, Massachusetts made up just shy of 15% of the national drug development pipeline and approximately 7% of the global drug development pipeline."
Andrea Confetti and Roberto Fanelli
EXCLUSIVE SYNTHESIS BU LEADER (AC) & CATALOGUE APIS BU LEADER (RF), DIPHARMA FRANCIS
"Dipharma is proud to have been reliably serving the life sciences industry for decades and will continue to do so for many years to come."
Trevor P. Castor
PRESIDENT & CEO, APHIOS
"Aphios, which means virus-free, has the core mission to not only contain viruses but also to treat underlying infectious diseases."
Milton Boyer and David Stevens
CEO (MB) & CCO (DS), KINDEVA DRUG DELIVERY
"A shift in pharma’s pipeline catalyzes a need for changes to CDMOs’ capacity."
Paolo Paissoni
DIRECTOR OF INNOVATION AND BUSINESS DEVELOPMENT, PROCOS SPA
"We are currently building a new workshop in which we are specifically going to add small-scale lines to support clinical trial supply and generic product manufacturing."
Louis P. Kassa III
PRESIDENT AND CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"We want scientists to focus on science, and we offer them the equipment and services so they can do that."
Debbie Hart
PRESIDENT, BIONJ
"We used our voice to educate on the value of medical innovation and boasted the strength of New Jersey’s vibrant ecosystem, which was responsible for more than 50% of all novel FDA approvals in 2023."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
